All In Biotech

BLA 022542 · Viokace

Viokace

Pancrelipase (Amylase, Lipase, Protease) · Oral

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Mar 1, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

n/a

n/a Phase 3, n/a recruiting

FAERS reports

2,537

2,257 serious, 286 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 14, 2025.

1. INDICATIONS AND USAGE VIOKACE, in combination with a proton pump inhibitor, is indicated for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in adults. VIOKACE, in combination with a proton pump inhibitor, is indicated for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy in adults. ( 1 )

Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglycerides, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 1, 2012 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelReviewLetter
2 products under this application
  • VIOKACE · PANCRELIPASE (AMYLASE 39,150USP UNITS; LIPASE 10,440USP UNITS; PROTEASE) 39,150USP UNITS · TABLET, ORAL · Prescription
  • VIOKACE · PANCRELIPASE (AMYLASE 78,300USP UNITS; LIPASE 20,880USP UNITS; PROTEASE) 78,300USP UNITS · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.

All n/a trials
ClinicalTrials.gov returned an error (400). The numbers below may be missing or incomplete.

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea256
  • nausea158
  • dyspnoea135
  • fatigue133
  • off label use131
  • vomiting126
  • abdominal pain118
  • asthenia118
  • pyrexia115
  • pain108
  • weight decreased107
  • drug ineffective98

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200516
200610
200713
200812
200921
201045
201149
201253
201366
201456
201593
201698
2017103
2018118
2019141
2020170
2021235
2022271
2023260
2024276
2025269
2026140

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Viokace (Lipase/Protease/Amylase)

2024 spending

$2.7M

Beneficiaries

679

2,062 claims

Per beneficiary

$3,981

$5.83 per unit

View as table
YearSpending
2020$0
2021$1,743,703
2022$2,824,115
2023$2,582,612
2024$2,703,061

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Viokace

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.